http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Mar 2026 09:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html si-local-file:///var/storage/secattach/20260310/26136784.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html Tue, 10 Mar 2026 09:11:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html si-local-file:///var/storage/secattach/20260310/26136784.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html Tue, 10 Mar 2026 09:11:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html si-local-file:///var/storage/secattach/20260310/26136784.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html Tue, 10 Mar 2026 09:11:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html si-local-file:///var/storage/secattach/20260310/26136784.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CITIUS+ONCOLOGY%2C+INC.+++++For%3A+Mar+10/26136784.html Tue, 10 Mar 2026 09:11:00 -0400 CTOR CTXR O.11391251 O.54377330 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Mar+10/26136700.html si-local-file:///var/storage/secattach/20260310/26136700.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Mar+10/26136700.html Tue, 10 Mar 2026 09:04:00 -0400 CTXR O.11391251 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Mar+10/26136700.html si-local-file:///var/storage/secattach/20260310/26136700.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Citius+Pharmaceuticals%2C+++For%3A+Mar+10/26136700.html Tue, 10 Mar 2026 09:04:00 -0400 CTXR O.11391251 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html <p>Citius Oncology Inc. (NASDAQ: CTOR) announced topline results from a completed investigator-initiated Phase 1 clinical trial evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers.</p> <p>The University of Pittsburgh-led dose-escalation study enrolled 25 evaluable patients with recurrent or metastatic gynecologic cancers, including ovarian and endometrial malignancies. The trial found no unexpected safety signals or serious immune-related adverse events at any dose level tested.</p> <p>Among 21 evaluable patients, the study demonstrated a 24% objective response rate and a 48% clinical benefit rate, defined as complete response, partial response or stable disease for six months or greater. The trial http://www.streetinsider.com/FDA/Citius+Oncology+reports+phase+1+trial+results+for+gynecologic+cancers/26136210.html Tue, 10 Mar 2026 08:47:20 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330 http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html <div class="xn-content"> <p class="prntac"><i>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</i></p><p class="prntac"><i>Topline data of <span>University of Pittsburgh-led</span> trial to be presented at an upcoming international cancer conference later this year</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.craord" idsrc="xmltag.org" >CRANFORD, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology, Inc.</span> ("<span value="NASDAQ-NMS:CTOR" idsrc="xmltag.org" >Citius Oncology</span>") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of <span value="NASDAQ-SMALL:CTXR" idsrc="xmltag.org" >Citius Pharmaceuticals, Inc.</span> ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by <span value="ACORN:1787597764" http://www.streetinsider.com/Press+Releases/Citius+Oncology+Announces+Positive+Topline+Results+from+Investigator%E2%80%91Initiated+Phase+1+Study+of+LYMPHIR%E2%84%A2+in+Combination+with+Pembrolizumab+in+Relapsed+or+Refractory+Gynecologic+Cancers/26136205.html Tue, 10 Mar 2026 08:47:00 -0400 A.17875977 A.22847412 A.60001765 CTOR CTXR O.01402212 O.03960636 O.11391251 O.20738543 O.54377330